CN104127406A - Application of dihydromyricetin in preparing inhibitor for liver cell oxidative damage - Google Patents
Application of dihydromyricetin in preparing inhibitor for liver cell oxidative damage Download PDFInfo
- Publication number
- CN104127406A CN104127406A CN201410398304.8A CN201410398304A CN104127406A CN 104127406 A CN104127406 A CN 104127406A CN 201410398304 A CN201410398304 A CN 201410398304A CN 104127406 A CN104127406 A CN 104127406A
- Authority
- CN
- China
- Prior art keywords
- dihydromyricetin
- cell
- application
- oxidative damage
- urethanes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of dihydromyricetin in preparing an inhibitor for liver cell oxidative damage, and further discloses an application of dihydromyricetin in preparing an inhibitor for liver cell oxidative damage induced by ethyl carbamate. The application shows that dihydromyricetin can effective prevent oxidative damage induced by ethyl carbamate, can reduce generation of active oxygen and is a compound with a good development prospect; a novel medical application is provided for dihydromyricetin, and a novel application field is developed.
Description
Technical field
The present invention relates to the technical field of Chinese medicine application, the particularly application of a kind of dihydromyricetin in the inhibitor of preparing liver cell oxidative damage.
Background technology
Dihydromyricetin (Dihydromyricetin, DMY) be a kind of polyphenol hydroxyl flavanonol, this compound separates and obtains first from the leaf of Vitaceae ampelopsis A. Meliaefolia, after from the stem and leaf of Ampelopsis grossedentata, again separate and obtain this compound, chemistry (2R by name, 3R)-3,5,7-trihydroxy-2-(3,4,5-trihydroxy phenyl) 4-Chromanone, structural formula is as follows:
Research shows: in Ampelopsis grossedentata stem and leaf, dihydromyricetin cellulose content can reach more than 30%.
Ampelopsis grossedentata, formal name used at school Ampelopsis grossedentata (Ampelopsis grossedentata (Hand-Mazz) WT Wan), it is a kind of Wild Liane of Vitaceae Ampelopsis, mainly be distributed in the provinces and regions such as Guangxi, Guangdong, Yunnan, Guizhou, Hunan, Hubei, Jiangxi, Fujian, concentrated or scattered in the mixed forest on height above sea level 400～1300m hillside, be very to enrich and available wild plant resource.The main active of Ampelopsis grossedentata has the multiple efficacies such as the free radical of removing, antioxidation, antithrombotic, antitumor, antiinflammatory; And dihydromyricetin is at the sickness rate of removing ethylism, prevention alcoholic liver, fatty liver, the deterioration of inhibition hepatocyte, reduction hepatocarcinoma, improves the aspects such as SOD activity and hepatoprotective and there is special efficacy.
The Chinese patent literature that is CN10181221A as publication number discloses the purposes of a kind of dihydromyricetin in the medicine of preparation treatment gastric ulcer and gastritis.The Chinese patent literature that and for example publication number is CN101023942A discloses the application of dihydromyricetin at preparation prevention or Cardiovarscular.Prove through zoopery, dihydromyricetin has the antibody angular vein thrombotic effect similar to aspirin, the cardiovascular disease of anti-tampon initiation effectively.
Free radical is considered to cause one of reason that human senility and some chronic disease occur, when the free-radical generating in human body too much or removed when slow, will transfer attack various organelles and make it to sustain damage, thereby accelerate the aging course of body and bring out various diseases.
Urethanes (Ethyl Carbamate, be called for short EC, claim again Urethane), there is genetoxic and carcinogenecity, 2007, international cancer research institution (IARC) formally classified as urethanes 2A class carcinogen (mankind's possibility carcinogen).Find that after deliberation urethanes is the product of following in the preparation process of fermented food (bread, clabber, soy sauce, fermented bean products etc.) and alcoholic beverage (wine, applejack, Chinese rice wine, sake etc.).
Liver is the metabolic vitals of human body, if liver cell damaged, human health will be affected.Therefore, developing a kind of hepar damnification that urethanes is caused, to have the medicine of protective effect be necessary.
Summary of the invention
The invention provides the new purposes of a kind of dihydromyricetin in the inhibitor of preparing liver cell oxidative damage, expanded the application of dihydromyricetin.
The application of a kind of dihydromyricetin in the inhibitor of preparing liver cell oxidative damage.
Application in the inhibitor of the liver cell oxidative damage that further, dihydromyricetin is induced by urethanes in preparation.
The application of the pharmaceutical composition of acceptable additives composition in the inhibitor of preparing liver cell oxidative damage taking dihydromyricetin as active component and on pharmacopedics, especially for the application in the inhibitor of the liver cell oxidative damage of being induced by urethanes.
Described inhibitor can be tablet, capsule or beverage.
As preferably, in described inhibitor, the effective dose of dihydromyricetin is 2.5～10 μ g/mL.
Dihydromyricetin in the present invention can directly obtain by commercial sources;
Or extract and obtain by existing conventional method.
Compared with prior art, the present invention has the following advantages:
The present invention has found the oxidative damage that dihydromyricetin can effectively anti-urethanes induction first, reduces the generation of active oxygen, is a compound with good DEVELOPMENT PROSPECT;
The present invention, for dihydromyricetin provides new medical application, has expanded a new application.
Brief description of the drawings
Fig. 1 is dihydromyricetin ABTS total antioxidant capacity;
Fig. 2 is dihydromyricetin DPPH radical scavenging activity;
Fig. 3 is the protective effect of the HepG2 cellular oxidation damage of dihydromyricetin to urethanes induction;
Fig. 4 is the inhibitory action that dihydromyricetin generates the HepG2 cytoactive oxygen-derived free radicals ROS (DCF fluorescence) of urethanes induction;
Fig. 5 is the protective effect of the HepG2 mitochondrial membrane potential in anoxic (MMP) of dihydromyricetin to urethanes induction;
Fig. 6 is the HepG2 cell mitochondrial membrane lipid snperoxiaized protective effect of dihydromyricetin to urethanes induction;
Fig. 7 is the inhibitory action that dihydromyricetin reduces the HepG2 cell glutathione content of urethanes induction;
Fig. 8 is the inhibitory action of the HepG2 nucleus damage of dihydromyricetin to urethanes induction.
Detailed description of the invention
Below in conjunction with specific embodiment, the invention will be further described, and what below enumerate is only specific embodiments of the invention, but protection scope of the present invention is not limited in this:
Embodiment 1 dihydromyricetin tablet
According to mass fraction:
Dihydromyricetin 50%, starch 17.3%, lactose 25%, crosslinked carboxymethyl fecula sodium 7%, magnesium stearate 0.7%.
According to the mass fraction of above-mentioned formula, by 75 grams of dihydromyricetin, 25.95 grams of starch are dissolved in 150 grams of water, the dry dihydromyricetin microcapsule granule of making of spraying.By microcapsule grain and 37.5 grams of lactose, 10.5 grams, crosslinked carboxymethyl fecula sodium, 1.05 grams of mixing of magnesium stearate, join in three-dimensional motion mixer, and incorporation time is 15-20 minute, obtains total mixture.Then direct compression obtains 1000 altogether, and every 0.15 gram, 75 milligrams/of dihydromyricetin cellulose contents.
Dosage for being grown up: take each 1 every day 2 times.
Embodiment 2 dihydromyricetin cellulose capsules
According to mass fraction:
Dihydromyricetin 30%, gelatin 18%, phosphopeptide caseinate 27.5%, magnesium stearate 1.5%, D-mannital 23%.
According to the mass fraction of above-mentioned formula, by 30 grams of dihydromyricetin, 18 grams, gelatin, is dissolved in 150 grams of water, the dry dihydromyricetin microcapsule granule of making of spraying.27.5 grams of phosphopeptide caseinates, 23 grams of D-mannitals, 1.5 grams of magnesium stearate and microcapsule granule are put into the abundant mix homogeneously of multidigit mixer, make wet grain, cross 20 mesh sieves, dry, and granulate is made capsule with capsule filler subpackage.250 milligrams/, 75 milligrams/of dihydromyricetin cellulose contents.
Dosage for being grown up: take each 1 every day 2 times.
Embodiment 3 dihydromyricetin beverages
According to mass fraction:
Dihydromyricetin 0.375%, citric acid 0.1%, Mel 4.35%, aspartame 1.5%, vanilla 0.05%, water 93.625%.
According to the mass fraction of above-mentioned formula, by 37.5 grams of dihydromyricetin, 10 grams of citric acids, 435 grams of Mel, 150 grams of aspartames, 5 grams of vanillas of Rhizoma et radix valerianae, 9362.5 grams of water mix homogeneously, boil, sterile filling carafe and get final product.Every bottle of 200mL, 75 milligrams/bottle of dihydromyricetin cellulose contents.
Dosage for being grown up: take each 1 bottle every day 2 times.
Performance test
By the Antioxidation in vitro of antioxidation measuring dihydromyricetin
(1) ABTS experiment
ABTS[2,2-azino-bis-(3-ethyl-benzothiazole-6-sulfonic acid)] method can be used for measuring the oxidation resistance of biological sample.ABTS generates stable aeruginous radical cation ABTS after active oxygen oxidation
+if, tested material energy and ABTS
+react and reaction system is faded, pointing out tested material to there is reduction ABTS
+the activity of free radical.
Preparation ABTS
+working solution, at 700 μ L ABTS
+in working solution, add the sample liquid of 20 μ L containing dihydromyricetin, fully mix, under room temperature condition, react 6min (lucifuge), measure the absorbance A under 734nm
i, replace sample liquid to do blank with the distilled water of equivalent, remember that its absorbance is A
0.Using Trolox (No. CAS as 53188-07-1) as positive control.
ABTS
+free radical scavenging activity (%)=[(A
0-A
i)/A
0] × 100%
As shown in Figure 1, the total antioxidant capacity of dihydromyricetin is dose dependent and increases within the scope of 0-20 μ g/mL, and when free radical scavenging activity is 50%, required dihydromyricetin dosage is 8.44 μ g/mL.
(2) DPPH experiment
As a kind of stable free radical, DPPH can catch (" removing ") other free radical.Whether the speed of therefore observing a certain chemical reaction after DPPH by adding slows down, and whether has the index of radical reaction essence as this reaction.Because DPPH free radical is locate to have strong absorption centered by 517nm, therefore in solution, presents darkviolet, and after being neutralized, can become colorless or light yellow.Utilize this characteristic process of detection reaction intuitively, by recording DPPH in the amount that can obtain initial free radical at 517nm absorbance.
In the centrifuge tube of 1.5mL, add successively 700 μ L, 0.1mM DPPH solution and the 20 μ L sample liquid containing dihydromyricetin, fully mix, under the room temperature condition of darkroom, react, after 30min, survey light absorption value at 517nm wavelength place, be designated as A
i; In test tube, add 700 μ L DPPH solution and 20 μ L water, after mixing, place 30min at dark place, under 517nm, measure its absorbance, be designated as A
0as blank.
DPPH free radical scavenging activity (%)=[(A
0-A
i)/A
0] × 100%
As shown in Figure 2, dihydromyricetin oxidation resistance is dose dependent and increases within the scope of 0-10 μ g/mL, and when free radical scavenging activity is 50%, required dihydromyricetin dosage is 4.08 μ g/mL.
The protective effect of the liver cell oxidative damage of dihydromyricetin to urethanes induction
(1) cell survival rate is measured (mtt assay)
Adopt mtt assay to detect the survival rate of cell.Select the cell of exponential phase, with 0.25% trypsinization cell monolayer, be made into individual cells suspension by the RPIM1640 culture medium that contains 10% new Ox blood serum, seed cells into that in 96 porocyte culture plates, (concentration is 4 × 10
3individual cells/well), hatch after 24h; Use respectively the dihydromyricetin pretreatment 24h of 2.5 μ g/mL and 5 μ g/mL, then process HepG2 cell 24h with 62.5mM urethanes, then use MTT (0.5mg/mL) to hatch 4h.The precipitate generating is dissolved in the DMSO of 150 μ L, detects the absorbance at 490nm place by microplate reader.
Cell survival rate (%)=[A
sample/ A
blank] × 100%
As shown in Figure 3, the dihydromyricetin solution effects of 2.5 μ g/mL and 5 μ g/mL dosage is in HepG2 cell (being designated as respectively 62.5EC+2.5DMY and 62.5EC+5DMY), compared with urethanes group (being designated as 62.5mM EC), cell quantity showed increased, cell survival rate has increased respectively 14.6% and 9.8%.Above-mentioned experimental result has confirmed that urethanes has protective action to liver cell oxidative damage.
(2) ROS horizontal detection (DCF fluorescence) in cell
Utilize fluorescent probe DCFH-DA to carry out active oxygen detection, itself does not have fluorescence DCFH-DA, can pass freely through cell membrane, enters after cell, can be generated DCFH by intracellular esterase hydrolyzed.And DCFH can not penetrating cell membrane, thereby make probe be easy to be loaded onto in cell.Intracellular active oxygen can be oxidized non-blooming DCFH and generate the DCF that has fluorescence.The fluorescence intensity that detects DCF just can be known the level of reactive oxygen species, and DCF fluorescence is stronger, and ROS is more.
Select the cell of exponential phase, with 0.25% trypsinization cell monolayer, use containing the RPIM1640 culture medium of 10% new Ox blood serum and be made into individual cells suspension, with 4x10
4the density in individual/hole is inoculated in 12 orifice plates, put and in incubator, cultivate sucking-off culture medium after 24h, adding respectively whole dosage is the dihydromyricetin of 2.5 μ g/mL and 5 μ g/mL, use again urethanes (62.5mM) to process liver cell 24h, wash 2 times with PBS, add the DCFH-DA dyeing 30min of 10 μ M, dyestuff clean after with fluorescence microscope and take pictures, and calculate average optical density value.
As shown in Figure 4, urethanes can cause HepG2 cell and produces a large amount of reactive oxygen free radical ROS (compared with Normal group, fluorescence intensity is 196.36%); Dosage is that 2.5 μ g/mL and 5 μ g/mL dihydromyricetin cellulose solutions all can significantly reduce ROS level in cell, and cell ROS fluorescence intensity has reduced respectively 40.81% (62.5EC+2.5DMY) and 28.06% (62.5EC+5DMY).The above results shows that dihydromyricetin cellulose solution can reduce ROS in born of the same parents and generate and accumulation, thereby intervenes the oxidative damage of liver cell.
(3) mitochondrial membrane potential in anoxic MMP horizontal detection
Select the cell of exponential phase, with 0.25% trypsinization cell monolayer, use containing the RPIM1640 culture medium of 10% new Ox blood serum and be made into individual cells suspension, with 4 × 10
4the density in individual/hole is inoculated in 12 orifice plates, put and in incubator, cultivate sucking-off culture medium after 24h, adding respectively whole dosage is 2.5 μ g/mL and 5 μ g/mL dihydromyricetin solution effects 24h, use again urethanes (62.5mM) to process liver cell 24h, wash 2 times with PBS, then adopt mitochondrial membrane potential probe Rhodamine 123 (RH123) fluorescent probe to dye, hatch 30min for 37 DEG C, after being cleaned, dyestuff with fluorescence microscope and take pictures, then analyzes its fluorescence intensity.
Mitochondrial membrane potential variation is associated with the generation of reactive oxygen free radical (ROS).Mitochondrion is the structure of manufacturing energy in cell, and the vigor of it and cell is closely related, and mitochondrial membrane potential can effectively reflect the functional status of intracellular plastochondria.As shown in Figure 5, compared with matched group (control), through 62.5mM urethanes effect HepG2 cell 24h, cell membrane potential significantly reduces (fluorescence intensity 52.68%), the dihydromyricetin of 2.5 μ g/mL and 5 μ g/mL dosage all can significantly suppress the reduction of the cell membrane potential of urethanes induction, and cell membrane potential fluorescence intensity is elevated to respectively 63.95% (62.5EC+2.5DMY) and 77.65% (62.5EC+5DMY).The above results shows that dihydromyricetin cellulose solution can effectively suppress the cell membrane potential reduction of urethanes induction.
(4) the snperoxiaized detection of cell mitochondrial membrane lipid
Select the HepG2 cell of exponential phase, with 0.25% trypsinization cell monolayer, use containing the RPIM1640 culture medium of 10% new Ox blood serum and be made into individual cells suspension, with 4 × 10
4the density in individual/hole is inoculated in 12 orifice plates, put and in incubator, cultivate sucking-off culture medium after 24h, adding respectively whole dosage is 2.5 μ g/mL and 5 μ g/mL dihydromyricetin solution effects 24h, use again urethanes (62.5mM) to process liver cell 24h, wash 2 times with PBS, add the NAO dyeing 30min of 10 μ M, dyestuff clean after with fluorescence microscope and take pictures, and calculate average optical density value.
A large amount of generations of ROS may cause the lipid peroxidation of mitochondrial membrane, can detect whether lipid peroxidation of cell membrane with NAO.As shown in Figure 6, compared with matched group (control), through 62.5mM urethanes effect HepG2 cell, NAO fluorescence intensity drops to 75.40%, dihydromyricetin 2.5 μ g/mL solution can significantly suppress the cell mitochondrial membrane lipid peroxidating of urethanes induction, and NAO fluorescence intensity is elevated to respectively 97.15%.
(5) glutathion inside cell GSH horizontal detection
Collect the HepG2 cell of logarithmic (log) phase, seed cells into that in 12 porocyte culture plates, (concentration is 4 × 10
4individual cells/well), hatch after 24h; Under the condition that contains 2.5 μ g/mL and 5 μ g/mL dosage dihydromyricetin cellulose solutions, act on 24h, with urethanes (62.5mM) processing HepG2 cell 24h, then with the dyeing of GSH fluorescent probe, hatch 30min for 37 DEG C, after being cleaned, dyestuff with fluorescence microscope and take pictures, then analyzes its fluorescence intensity.
GSH, as a kind of regulator of good Cellular Oxidation reducing condition, can remove oxygen-derived free radicals, and the oxidative damage due to poisonous substance is had to protective effect.As shown in Figure 7, compared with matched group (control), through 62.5mM urethanes effect HepG2 cell 24h, cell glutathione content significantly reduces (fluorescence intensity 74.83%).The cell glutathione content that the dihydromyricetin cellulose solution of 2.5 μ g/mL and 5 μ g/mL dosage all can suppress urethanes induction effectively reduces, and glutathione content is elevated to respectively 83.73% (62.5EC+2.5DMY) and 77.74% (62.5EC+5DMY).The above results shows that dihydromyricetin can suppress the reduction of the cell glutathione content of urethanes induction.
(6) Hoechst nucleus detects
Hoechst 33258 is a kind of blue fluorescent dyes that can permeates cell membranes, lower to the toxicity of cell, can be used for nucleus dyeing.Hoechst 33258 is specific DNA dyestuff, closes with A-T bond, can dye immediately to dead cell or through the fixing cell of 70% cold ethanol.Be gradual for the dyeing of living cells, in 10min, reach capacity.Observe under fluorescence microscope, living cells core is the even fluorescence of disperse, while there is apoptosis, and the visible dense fine and close particulate mass fluorescence that dyes in nucleus or Cytoplasm.
Select the cell of exponential phase, with 0.25% trypsinization cell monolayer, use containing the RPIM1640 culture medium of 10% new Ox blood serum and be made into individual cells suspension, with 4 × 10
4the density in individual/hole is inoculated in 12 orifice plates, put and in incubator, cultivate sucking-off culture medium after 24h, adding whole dosage is 2.5 μ g/mL and 5 μ g/mL dihydromyricetin cellulose solution pretreatment 24h, use again urethanes (62.5mM) to process liver cell 24h, wash 2 times with PBS, add the Hoechst 33258 of the 10 μ M 30min that dyes, dyestuff clean after with fluorescence microscope and take pictures.
Can be observed by Fig. 8, normal HepG2 cell (control) nucleus volume is larger, chromatin is homogeneous, through 62.5mM urethanes effect HepG2 cell 24h, the chromatin of part cell has obviously occurred concentrated, and there is apoptotic body, and add after dihydromyricetin (2.5 μ g/mL and 5 μ g/mL) the pretreatment 24h of various dose, chromatin is slightly unfolded, karyomorphism recovers to some extent, shows that dihydromyricetin can suppress the nucleus damage of urethanes induction.
Finally, the present invention can summarize with other the concrete form without prejudice to spirit of the present invention and principal character.Therefore, no matter from that, above-mentioned embodiment of the present invention all can only think explanation of the present invention can not limit the present invention, claims have been pointed out scope of the present invention, and scope of the present invention is not pointed out in above-mentioned explanation, therefore, any change in implication and the scope suitable with claims of the present invention, all should think to be included in the scope of claims.
Claims (5)
1. the dihydromyricetin application in the inhibitor of preparing liver cell oxidative damage.
2. the application in the inhibitor of the liver cell oxidative damage that a dihydromyricetin is induced by urethanes in preparation.
3. the application of the pharmaceutical composition of an acceptable additives composition taking dihydromyricetin as active component and on pharmacopedics in the inhibitor of preparing liver cell oxidative damage.
4. the application taking dihydromyricetin as active component and in the inhibitor of the liver cell oxidative damage that on pharmacopedics, the pharmaceutical composition of acceptable additives composition is induced by urethanes in preparation.
5. according to the application described in the arbitrary claim of claim 1～4, it is characterized in that, in described inhibitor, the effective dose of dihydromyricetin is 2.5～10 μ g/mL.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410398304.8A CN104127406B (en) | 2014-08-12 | 2014-08-12 | The application in the inhibitor preparing liver cell oxidative damage of a kind of dihydromyricetin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410398304.8A CN104127406B (en) | 2014-08-12 | 2014-08-12 | The application in the inhibitor preparing liver cell oxidative damage of a kind of dihydromyricetin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104127406A true CN104127406A (en) | 2014-11-05 |
| CN104127406B CN104127406B (en) | 2016-08-24 |
Family
ID=51800430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410398304.8A Active CN104127406B (en) | 2014-08-12 | 2014-08-12 | The application in the inhibitor preparing liver cell oxidative damage of a kind of dihydromyricetin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104127406B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104496955A (en) * | 2014-12-01 | 2015-04-08 | 华中科技大学同济医学院附属同济医院 | Five different crystalline form substances of dihydromyricelin |
| CN111494359A (en) * | 2020-04-29 | 2020-08-07 | 上海爱启医药技术有限公司 | Dihydromyricetin with alcohol effect dispelling function |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103271901A (en) * | 2013-04-03 | 2013-09-04 | 广东医学院附属医院 | Application of dihydromyricetin (DHM) in preparation of anti-hepatoma medicines |
| CN103751173A (en) * | 2014-01-06 | 2014-04-30 | 广东医学院附属医院 | Application of dihydromyricetin in preparation of liver regeneration medicine |
-
2014
- 2014-08-12 CN CN201410398304.8A patent/CN104127406B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103271901A (en) * | 2013-04-03 | 2013-09-04 | 广东医学院附属医院 | Application of dihydromyricetin (DHM) in preparation of anti-hepatoma medicines |
| CN103751173A (en) * | 2014-01-06 | 2014-04-30 | 广东医学院附属医院 | Application of dihydromyricetin in preparation of liver regeneration medicine |
Non-Patent Citations (1)
| Title |
|---|
| 钟正贤等: "广西藤茶中双氢杨梅树皮素保肝作用的实验研究", 《中国中医药科技》, vol. 9, no. 3, 31 December 2002 (2002-12-31), pages 155 - 156 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104496955A (en) * | 2014-12-01 | 2015-04-08 | 华中科技大学同济医学院附属同济医院 | Five different crystalline form substances of dihydromyricelin |
| CN111494359A (en) * | 2020-04-29 | 2020-08-07 | 上海爱启医药技术有限公司 | Dihydromyricetin with alcohol effect dispelling function |
| WO2021217823A1 (en) * | 2020-04-29 | 2021-11-04 | 上海爱启医药技术有限公司 | Dihydromyricetin having function of dispelling effects of alcohol |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104127406B (en) | 2016-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Phrueksanan et al. | Protection of Clitoria ternatea flower petal extract against free radical-induced hemolysis and oxidative damage in canine erythrocytes | |
| Simões et al. | Effect of Brazilian green propolis on the production of reactive oxygen species by stimulated neutrophils | |
| Yang et al. | Hypolipidemic and antioxidant effects of mulberry (Morus alba L.) fruit in hyperlipidaemia rats | |
| Türk et al. | Effects of pomegranate juice consumption on sperm quality, spermatogenic cell density, antioxidant activity and testosterone level in male rats | |
| Berté et al. | Chemical composition and antioxidant activity of yerba-mate (Ilex paraguariensis A. St.-Hil., Aquifoliaceae) extract as obtained by spray drying | |
| Prasad et al. | Antioxidant capacities of peel, pulp, and seed fractions of Canarium odontophyllum Miq. fruit | |
| Han et al. | Free radical scavenging effect of Diospyros kaki, Laminaria japonica and Undaria pinnatifida | |
| Di Pietro et al. | Role of polyphenols and carotenoids in endothelial dysfunction: An overview from classic to innovative biomarkers | |
| Alimi et al. | Protective effect of Opuntia ficus indica f. inermis prickly pear juice upon ethanol-induced damages in rat erythrocytes | |
| Strugała et al. | Antioxidant activity and anti‐inflammatory effect of fruit extracts from blackcurrant, chokeberry, hawthorn, and rosehip, and their mixture with linseed oil on a model lipid membrane | |
| Ali et al. | Antioxidant potential, subacute toxicity, and beneficiary effects of methanolic extract of pomelo (Citrus grandis L. Osbeck) in long evan rats | |
| Chan et al. | Polyphenol-rich extract from mulberry leaf inhibits vascular smooth muscle cell proliferation involving upregulation of p53 and inhibition of cyclin-dependent kinase | |
| CN103156193A (en) | Coenzyme Q10 soft capsules and preparation method thereof | |
| CN103652859B (en) | A kind of health food with anti-oxidation function and preparation method thereof | |
| AZEVEDO NOVELLO et al. | Chemical characterization, antioxidant and antiatherogenic activity of anthocyanin-rich extract from Euterpe edulis Mart. in mice. | |
| CN106474145B (en) | Application of the Polysaccharides from Leaves of Moringa oleifera in preparation prevention and treatment alcoholic liver injury drug and food | |
| KR101298568B1 (en) | Anti-obesity food composition containing extract of arctium lappa l | |
| Huang et al. | Simultaneous recovery of glycyrrhizic acid and liquiritin from Chinese licorice root (Glycyrrhiza uralensis Fisch) by aqueous two-phase system and evaluation biological activities of extracts | |
| CN104127406B (en) | The application in the inhibitor preparing liver cell oxidative damage of a kind of dihydromyricetin | |
| Asgharpour et al. | Antioxidant activity and glucose diffusion relationship of traditional medicinal antihyperglycemic plant extracts | |
| CN101738446A (en) | Method and system for electro chemical analysis of antioxidant in cosmetics | |
| Petchsomrit et al. | Green extraction of Buchanania siamensis and water-based formulations | |
| Xin-Mei et al. | Centranthera grandiflore alleviates alcohol-induced oxidative stress and cell apoptosis | |
| CN101433564B (en) | Use of water chestnut extract in preparing medicament for treating leukaemia | |
| Orsine et al. | Determination of chemical antioxidants and phenolic compounds in the Brazilian Mushroom Agaricus sylvaticus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |